Merus Labs International Inc. Announces Promotion & Distribution Agreements for Emselex(R)/Enablex(R) in Canada & Slovenia

Merus Labs International Inc. Announces Promotion & Distribution Agreements for 
Emselex(R)/Enablex(R) in Canada & Slovenia 
TORONTO, ONTARIO -- (Marketwire) -- 02/19/13 -- Merus Labs
International Inc. ("Merus" or the "Company") (TSX:MSL)(NASDAQ:MSLI)
is pleased to announce that through its wholly owned subsidiaries,
Merus Labs Netherlands B.V and Merus Labs Luxco S.a R.L., it has
entered into promotion and distribution agreements with partners in
Canada and Slovenia for the Company's Emselex(R)/Enablex(R) product.
Emselex(R)/Enablex(R) (darifenacin) is a branded prescription
medicine in extended release tablet form which is a muscarinic
antagonist indicated for the treatment of overactive bladder with
symptoms of urge urinary incontinence, urgency, and frequency.  
The partner companies and corresponding territories are as follows;
NorrizonRx Sales and Marketing Group Inc. (Canada) and Proksimum
Pharma d.o.o. (Slovenia). Under the terms of the agreements, the
partner companies have been granted exclusive rights to market and
sell Emselex(R)/Enablex(R) in their respective territories. The
financial terms of the agreements have not been disclosed. For the
year 2012, the newly partnered territories had net sales of
approximately US$4.5 million.  
About Merus Labs International Inc.  
Merus is a specialty pharmaceutical company engaged in the
acquisition and licensing of pharmaceutical products. The Company
utilizes its expertise in pharmaceutical markets and its access to
capital to acquire and license niche branded products. Merus further
enhances the sale and distribution of these products by the
introduction of a focused marketing and promotion plan. 
Cautionary Statement  
Certain statements contained in this press release may constitute
"forward-looking statements" within the meaning of Section 21E (i)
(1) of the United States Securities Exchange Act of 1934. Such
forward-looking statements involve known and unknown risks,
uncertainties and other factors that may cause Merus' actual results
to be materially different from any future results expressed or
implied by these statements. Such factors include the following:
general economic and business conditions, changes in demand for
Merus' products, changes in competition, the ability of Merus to
integrate acquisitions or complete future acquisitions, interest rate
fluctuations, currency exchange rate fluctuations, dependence upon
and availability of qualified personnel and changes in government
regulation. In light of these and other uncertainties, the
forward-looking statements included in this press release should not
be regarded as a representation by Merus that Merus' plans and
objectives will be achieved. These forward-looking statements speak
only as of the date of this press release, and we undertake no
obligation to update or revise the statements.
Merus Labs International Inc.
Elie Farah
President and CEO
(416) 593-3701
Press spacebar to pause and continue. Press esc to stop.